Regeneron Pharmaceuticals
REGN
542 hedge funds and large institutions have $25.3B invested in Regeneron Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 223 increasing their positions, 184 reducing their positions, and 53 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 223 | Existing positions reduced: 184
2% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 53
0% more funds holding in top 10
Funds holding in top 10: 13 → 13 (0)
3% less capital invested
Capital invested by funds: $26.2B → $25.3B (-$856M)
1% less funds holding
Funds holding: 550 → 542 (-8)
11% less call options, than puts
Call options by funds: $630M | Put options by funds: $707M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$322M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$306M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$120M |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$89.5M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$87.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$849M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
-$280M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$252M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$83.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$69.2M |
REGN Hedge Fund Activity: Q2 2016 in Review
542 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2016, worth a combined $25.3B — down 3.3% from $26.2B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new REGN positions and 53 closed out — a net gain of 1 holder — while 223 added to existing stakes and 184 trimmed.
The largest buyer was Winslow Capital Management, opening a new position worth an estimated $322M. The largest seller was T. Rowe Price Associates, cutting an estimated $849M.
- 542 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2016, down from 550 in Q1 2016.
- Funds reported $25.3B of Regeneron Pharmaceuticals stock for Q2 2016, down 3.3% quarter-over-quarter.
- 54 funds opened new Regeneron Pharmaceuticals positions in Q2 2016 and 53 closed out, a net change of +1 holder.
- The largest Regeneron Pharmaceuticals buyer in Q2 2016 was Winslow Capital Management, an estimated $322M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2016 was T. Rowe Price Associates, an estimated $849M sold.
Based on aggregated 13F filings for Q2 2016.